Anterior Myocardial Infarction
3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Sungen BiomedicalChina - Beijing
3 programs2
1
SGC001Phase 21 trial
SGC001Phase 11 trial
SGC001Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
Sungen BiomedicalSGC001
Sungen BiomedicalSGC001
Sungen BiomedicalSGC001
Miracor MedicalPiCSO Impulse System
Clinical Trials (4)
A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction
Start: Feb 2026Est. completion: Jun 2027
Phase 2Not Yet Recruiting
A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction
Start: Jan 2025Est. completion: Jul 2025
Phase 1Completed
A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects
Start: Aug 2024Est. completion: Jul 2025
Phase 1Completed
Effects of Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) Therapy on miRNAs Expression and Absolute Microvascular Resistance by Continuous Thermodilution in ST-segment Elevation Myocardial Infarction (STEMI) Patients: PiCSO-STEMI TRIAL
Start: Nov 2022Est. completion: Jun 2024
N/AWithdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space